had been hospitalized with a "viral syndrome" characterized by episodes of fever (temperatures р39.5ЊC), rash, sore throat, abdominal pain, postmicturition pain, back pain, and pain in his hands and feet that required narcotic analgesia. During that hospitalization he defervesced over 24 h without specific therapy. On a follow-up clinic visit, his CD4 count was 298 cells/mm 3 , and his virus load was 88,000 copies/mL. He restarted antiretroviral therapy with a regimen of stavudine-abacavir-ritonavir-saquinavir.
One week later, he returned to the clinic with a rash, sore throat, diffuse abdominal pain, nausea, anorexia, postmicturition pain, back pain, hand and foot pain, and daily episodes of fever (temperatures р38.3ЊC). Physical examination revealed bilateral bulbar conjunctivitis without exudate, an injected pharynx without exudate, a diffuse pruritic erythematous macular rash involving the trunk and extremities, including the palms and soles, and abdominal tenderness on palpation without rebound. Antiretroviral therapy was discontinued, and a course of methylprednisolone was prescribed.
The patient returned to the clinic 48 h later feeling worse. His rash had improved; however, his hands and feet were swollen and so painful that he was unable to sleep. The interim development of marked swelling of the hands and feet in association with episodes of fever, conjunctivitis, pharyngitis, and rash prompted consideration of Kawasaki disease. The patient was admitted and treated with 2 g/kg of pooled human gamma globulin (IVIG) over 12 h and aspirin (ASA) at a dosage of 1300 mg orally q6h (80 mg/kg per day divided into 4 equal doses). Within 24 h of completing the IVIG regimen, all the patient's protean symptoms had resolved, including the sore throat, pain in his hands and feet, pruritic rash, back pain, abdominal pain, and postmicturition pain. The patient did not resume antiretroviral therapy. The rash did not desquamate.
Five months after discharge, the patient was hospitalized again. He had experienced 5 days of fever (temperatures 38.9ЊC-39.4ЊC); bilateral conjunctivitis; sore throat; marked, painful swelling of the hands and feet; malaise; a diffuse pruritic erythematous rash on his trunk and extremities, including palms and soles; back pain; headaches; postmicturition pain; abdominal pain; and a mild, nonproductive cough. The conjunctivitis, rash, and painful swelling of the hands and feet appeared after 3-4 days of fever. He was not receiving antiretroviral therapy and had not begun receiving any new medication. Findings on physical examination were identical to those at his previous admission and included tender cervical adenopathy (lymph nodes all !1 cm in diameter). He was treated again with IVIG and ASA. He had a dramatic response to therapy, with all symptoms and rash resolving within 24 h of completing the IVIG therapy.
Patient 2. The second patient was a 40-year-old African American woman who had been HIV positive for 11 years. Medical history included hepatitis C and thrush. She had a complex antiretroviral history and was infected with a multidrug-resistant HIV virus. Her most recent CD4 count was 13 cells/mm 3 , and her virus load was 200,000 copies/mL. She was admitted to the hospital with a history of 4 days of fever (temperatures р38.3ЊC), malaise, headaches, anorexia, nausea with occasional vomiting, loose stools, abdominal pain, back pain, a mild cough, and a "dry" mouth and throat. The day before admission, she developed red eyes, painful swelling of the hands and feet, and a new pruritic rash. She was receiving dapsone and clarithromycin therapy. For the next 48 h, she had multiple episodes of fever (with temperatures as high as 40ЊC) without hypotension.
Findings of physical examination were remarkable for injected conjunctiva without exudates, a minimally injected oral pharynx, markedly swollen painful hands and feet (figure 1), a diffuse erythematous rash (including on the palms and soles), tender cervical adenopathy (lymph nodes all !1 cm in diameter), and moderate right upper quadrant pain induced by deep palpation. She had severe hand, foot, and back pain that required narcotic analgesics. After an intensive investigation failed to reveal either an infectious or noninfectious cause for her illness, Kawasaki-like syndrome was diagnosed and the patient was treated with IVIG and ASA. The patient's last episode of fever (temperature р39.2ЊC) occurred 2 h after the start of IVIG infusion; she was afebrile after that. The rash and pain in her hands, feet, and back resolved within hours of completing the IVIG therapy. She resumed prophylaxis with dapsone and clarithromycin that she had been receiving to prevent opportunistic infections without recurrence of the fevers or rash. Magnetic resonance angiography (MRA) was performed 17 days after her initial fever; it revealed no coronary artery aneurysms.
Results of diagnostic evaluation for possible infectious etiologies for both patients 1 and 2 are summarized in table 1. The results of laboratory tests for both patients are summarized in table 2.
DISCUSSION
Kawasaki disease is a clinical syndrome diagnosed by a constellation of signs and physical findings [11] . The diagnosis requires a history of fever of 5 days' duration (with temperatures usually у39ЊC), plus 4 of the following 5 associated physical findings: (1) bilateral nonpurulent conjunctivitis; (2) changes of the oropharynx, including injected pharynx, injected and/or dry fissured lips, and/or a strawberry tongue; (3) changes of the peripheral extremities, including edema and/or erythema of the hands and the feet (usually followed by desquamation); (4) a polymorphous, erythematous, nonvesicular exanthem; and (5) cervical lymphadenopathy (lymph nodes у1.5 cm in diameter). In addition to the above criteria, results of evaluation for other infectious or noninfectious causes must be negative.
The HIV-positive patients we studied had fever of у5 days' duration. Both patients had bulbar conjunctivitis without exudates, a diffuse erythematous rash, and marked, painful swelling and erythema of the hands and feet. Patient 1 had a sig- nificant pharyngitis without exudates. Patient 2 complained of a dry mouth and throat but had only mild injection of the lips and oropharynx on physical examination. Neither patient had a strawberry tongue. Both patients had tender cervical adenopathy, but no lymph nodes were у1.5 cm in diameter. Other prominent symptoms experienced by both patients included headache, nausea, anorexia, abdominal pain, loose stools, and considerable back pain (arthralgias). In both patients, fevers preceded appearance of the conjunctivitis, hand swelling, and rash by 3-4 days. Pronounced gastrointestinal symptoms, including abdominal pain, vomiting, and loose stools, also began before development of the rash and the painful swelling of the hands and feet. A rapid therapeutic response to IVIG is generally considered confirmatory for the clinical diagnosis of Kawasaki disease. Both patients rapidly responded to IVIG therapy on the 3 occasions that it was administered. Table 2 summarizes the signs, symptoms, and laboratory findings for the patients we studied and for the 7 previously described HIV-positive patients with Kawasaki-like syndromes. Kawasakilike syndromes in HIV-positive patients occurred in association with moderate to severe immune dysfunction (CD4 count, 10-298 cells/mm 3 ). Diagnosis of Kawasaki-like syndromes in HIV-positive patients is complex because of HIV-associated polypharmacy, which creates a risk of drug reactions, and because of possible opportunistic infections. Overall, the fever and physical findings necessary to make the diagnosis do not appear to be appreciably altered, except that the tender cervical adenopathy may not meet the criterion that the lymph nodes are у1.5-cm in diameter. Cervical adenopathy with lymph nodes у1.5 cm in diameter is the least common physical finding in children with Kawasaki disease. Gastrointestinal symptoms are very common in HIV-positive patients with Kawasakilike syndromes. Six of the 8 adult patients with HIV reported у1 of the following conditions: abdominal pain, nausea, anorexia, and diarrhea. Gastrointestinal complaints are less common in children (∼30%); however, this may be due to underreporting related to the age of the typical patient (∼2 years). Older children who develop Kawasaki disease commonly experience nausea, vomiting, diarrhea, and weight loss [12] .
In the absence of a known etiology or a "gold standard" for making the diagnosis, it is not known whether the pathophysiology of Kawasaki syndrome in adults or adults infected with NOTE. ASA, aspirin; ALAT, alanine aminotransferase; ASAT, aspartate aminotransferase; AZT, azidothymidine; Clm, clarithromycin; Dap, dapsone; ddC, zalcitabine; ddI, didanosine; ESR, erythrocyte sedimentation rate; INH, isoniazid; IVIG, iv human gamma globulin; ND, no data; NSA, not specifically addressed; OI, opportunistic infection; Pent, pentamidine; PE, pericardial effusion; Ph, injected pharynx; Pyr, pyrimethamine; ST, sinus tachycardia; StT, strawberry-colored tongue; TMP-SMZ, trimethoprim sulfamethoxazole; TR, tricuspid regurgitation; ϩ, present; Ϫ, absent.
HIV is the same as it is in children. Eight published reports of cases of HIV-positive adults with Kawasaki-like syndromes suggest that the syndrome is more common in association with the setting of HIV, although it is difficult to exclude the possibility of a reporting bias. A review of all reported cases of Kawasaki-like syndromes in HIV-positive patients suggests that they have a greater risk of relapse than do adult or pediatric patients without HIV infection. Three of 9 HIV-positive pa-tients (2 adults) with Kawasaki-like syndrome had у1 relapse. There are no reported cases of relapsing syndromes in HIVnegative adults with Kawasaki disease. Epidemiological studies of Japanese children report a Kawasaki disease relapse rate of 3%-4% [13] . In the United States, the relapse rate is 0.8% [14] .
Laboratory data serve a supportive role in making the diagnosis of Kawasaki disease. Common laboratory-detected abnormalities associated with the disease include a thrombocytosis, elevated sedimentation rate (ESR), elevated C-reactive protein (CRP) level, and mild liver function test abnormalities. Review of the summarized laboratory data shows that only 3 of the 6 HIV-positive adult patients for whom data were available had an elevated ESR or CRP level. None of the patients with HIV had thrombocytosis. Our review of the reported cases of Kawasaki-like syndromes in HIV-positive patients revealed no laboratory abnormality that was common to all patients. It may be worthwhile to check the levels of ESR, CRP, transaminases, lactic dehydrogenase, creatine phosphokinase, and to perform serial complete blood counts (to look for thrombocytosis during early convalescence). Abnormalities in the results of these laboratory tests can serve as markers of inflammation to guide decisions about the duration of ASA therapy. It is unclear whether patients with advanced HIV disease would be expected to have the same abnormalities in laboratory test results as do otherwise healthy children with Kawasaki disease.
Electrocardiograms in adult patients with Kawasaki disease show sinus tachycardia and nonspecific ST-T-wave changes. None of the HIV-positive patients with Kawasaki-like syndromes had significant electrocardiogram changes. Performance of transthoracic echocardiograms for adults with or without HIV appear to be of little diagnostic value because they are too insensitive to exclude coronary artery aneurysms [15] [16] [17] . An MRA may be the most practical way to assess HIVpositive patients with Kawasaki-like syndromes for coronary artery aneurysms [18] [19] [20] . Patient 2 had an MRA performed 17 days after her first fever that revealed no coronary artery aneurysms. On the basis of our limited experience, we would reserve this diagnostic evaluation for patients that have clinically significant chest pain without evidence of myocardial infarction. No HIV-positive patients underwent cardiac catheterization and no aneurysms have been reported in HIV positive patients with Kawasaki-like syndromes.
Untreated Kawasaki-like syndromes-that is, syndromes that were not treated with IVIG-ASA therapy-appear to have the same natural history in HIV-positive patients as does Kawasaki disease in noncompromised hosts. Four of the 9 patients in this review did not receive IVIG therapy. They had acute syndromes that ranged from 7 to 21 days in duration (the acute phase in children ranges from 1 to 4 weeks in duration). There were no deaths or unusual morbidity in any of the HIV-positive patients. As in immunocompetent hosts, the acute phase of Kawasaki-like syndromes appeared to be self-limiting.
CONCLUSION
Therapy with IVIG and ASA is recommended for adult patients who present within the first 10 days of their febrile illness [21] . In children, therapy with IVIG reduces morbidity and mortality from Kawasaki disease by decreasing the proportion of patients who have coronary artery aneurysm formation from 20% to 3%-4% [22] . At least 4 of the 5 HIV-positive patients who received IVIG therapy for Kawasaki-like syndromes responded to therapy. The 3 patients that received a single-dose regimen of 2 g/kg had complete clinical remissions (relief of all symptoms) within 24 h [6] . The patient who received 300 mg/kg per day for 4 days had a complete clinical response at 48-72 h [4] . It is unclear whether the patient who received 25 g per day for 5 days [9] responded to therapy or whether improvement represented the natural history of a self-limiting illness. Clinical trial data in pediatric Kawasaki disease supports the use of single-dose IVIG therapy with ASA [23] .
HIV-positive patients with Kawasaki-like syndromes who present within 10 days of the original fever should be treated with pooled IVIG at a dosage of 2 g/kg given over 10-12 h and ASA at a dosage of 80 mg/kg per day (divided into 4 equal doses) for 2 weeks, followed by low-dose ASA therapy for 4-6 weeks or until all signs of inflammation have resolved. Our practice, on the basis of a review of the literature, is to treat with ASA at a dosage of 80 mg/kg per day (maximum, 3 325-mg tablets q.i.d.) for 2 weeks followed by ASA at a dosage of 81-165 mg q.d. for 6 months. At 6 months, a dipyridamole thallium cardiac stress test is performed [24] and at that time ASA therapy is discontinued if no ischemia is identified. In addition to therapy with IVIG-ASA, it seems prudent to optimize highly active antiretroviral therapy for all HIV-positive patients with this syndrome. None of the HIV-positive patients reviewed for this report were receiving effective highly active antiretroviral therapy when they developed a Kawasaki-like syndrome. All patients should be evaluated for hyperlipidemia, hypertension, and use of tobacco. Appropriate interventions should be made to prevent progression of atherosclerosis because this is a recognized complication of Kawasaki disease.
The etiology of Kawasaki disease and Kawasaki-like syndromes in HIV-positive patients is not known. Original epidemiological work in Japan strongly suggested that an infectious agent, likely a virus, would spread through the population in epidemic fashion (temporally and geographically), recurring every 2-4 years [13] . The 2-4-year periodicity was compatible with the hypothesis that outbreaks of infection occur in accumulated cohorts of susceptible newborn infants. Epidemiclike outbreaks have also been documented in other countries, including the United States [14] . Kawasaki disease occurs in ∼2% of exposed siblings, which represents a 20-100-fold increased relative risk, calculated on the basis of the incidence of disease in the general population. Kawasaki disease is extremely uncommon in newborn infants who are !90 days old, suggesting early protection by passive immunity from maternal antibodies [25] . Coronary artery aneurysm formation may be the most specific finding associated with Kawasaki disease. The acute inflammatory infiltrate within aneurysmal vessel walls is composed of neutrophils and lymphocytes, and it first appears in the vessel intima or adventia, then progresses into the media [26] . A similar pathophysiologic sequence has been observed in the development of arterial aneurysms in immunocompromised mice infected with g-herpesvirus type 68 [27] . Multiple microbes have been implicated as potential pathogens that cause pediatric Kawasaki disease. However, firm data supporting any specific agent are lacking. Noninfectious causes have also been proposed [28, 29] .
Kawasaki-like syndromes in HIV-positive patients occurred in association with moderate to severe immune dysfunction. HIV infection compromises cellular immunity and therefore resistance to intracellular pathogens [30] . We suspect that the patients we studied were infected by or reactivated an intracellular infectious agent, most likely a virus. HIV-positive patients are susceptible to reinfection or reactivation of viral infections associated with childhood. The best examples of this are chronic parvovirus B19 infection and varicella zoster reactivation (shingles). Parvovirus B19 infection in adult HIVpositive patients responds rapidly to treatment with IVIG [31] , which provides a clear example of treatment of a common viral infection with passive transfer of antibody from the general population. Parvovirus B19 [32, 33] and human herpesvirus type 6 [34] have been implicated in the papular-purpuric "gloves and socks" syndrome that shares some clinical features with Kawasaki disease. Specific testing for these agents by means of diagnostic PCR technology resulted in a negative finding in our patients. Kawasaki disease is rare in adults. Among the few reported cases, HIV-positive patients have been disproportionately represented. Because of the complexity of the clinical course of HIV-positive patients and their propensity to develop rashes and fevers that often resolve without identification of a cause, we suspect that there may be more cases of Kawasaki-like syndromes in the community than have been diagnosed or reported. IVIG-ASA therapy can be reasonably considered for HIV-positive patients that present with a fever of у5 days' duration, bulbar conjunctivitis without exudates, swelling and pain in the hands and feet, a diffuse erythematous rash, and either an aseptic pharyngitis or tender cervical adenopathy (once other infectious and noninfectious etiologies have been ruled out). Increased awareness of the syndrome in HIV-positive patients may facilitate earlier therapeutic intervention and shorten an otherwise prolonged hospitalization for a symptomatic fever of unknown origin.
